JP2012508249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508249A5 JP2012508249A5 JP2011535698A JP2011535698A JP2012508249A5 JP 2012508249 A5 JP2012508249 A5 JP 2012508249A5 JP 2011535698 A JP2011535698 A JP 2011535698A JP 2011535698 A JP2011535698 A JP 2011535698A JP 2012508249 A5 JP2012508249 A5 JP 2012508249A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen atom
- compound
- amino
- nitrophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 13
- 102000006772 Acid Ceramidase Human genes 0.000 claims 8
- 108020005296 Acid Ceramidase Proteins 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 6
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrugs Drugs 0.000 claims 3
- 102000004201 Ceramidases Human genes 0.000 claims 2
- 108090000751 Ceramidases Proteins 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002148 esters Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 108010035597 sphingosine kinase Proteins 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000004434 sulfur atoms Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001687 destabilization Effects 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 230000002132 lysosomal Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 230000002797 proteolythic Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Claims (11)
- 下記化学式(Ib):
nは、0〜13の整数であり;
R1は、水素原子、OH、SH、NH2、Cl、Br、I、C(=O)OH、C(=O)NH2、NH(C=NH)NH2、NHR6、NR6R7、+N(R6)3及びN-複素環から成る群から選択され;
R2は、水素原子及びアルキル基から成る群から選択され;
R3は、水素原子、OH、NO2、NH2及びNHR9から成る群から選択され;
R4は、水素原子、CH3、CH2OH及びCH2O-C(=O)-CH(R8)NR6R7から成る群から選択され;
R5は、水素原子、OH、=O及びOC(=O)CH(R8)NR6R7から成る群から選択され、各R6、R7及びR8は独立して水素原子、アルキル基、アラルキル基及びアリール基から成る群から選択され;
R9は、C(=O)-(CH2)mR10であり、ここでmは5〜10の整数であり;
R10は、水素原子、アルキル基、シクロアルキル基、又は複素環であり;
Xは、酸素原子、NH及び硫黄原子から成る群から選択され;
Yは、CH2又はNHであり;
ここで、R4及びR5の少なくとも1つは、エステル部分を含む)
の化合物、又はこの化合物の医薬的に許容された塩である、酸性セラミダーゼを阻害するための化合物。 - R4がCH2O-C(=O)-CH(R8)NR6R7である請求項1に記載の化合物。
- R5がOC(=O)CH(R8)NR6R7である請求項1に記載の化合物。
- (a)請求項1〜4のいずれか一項に記載の化合物、及び(b)医薬的に許容された担体から成る、患者における好ましくないセラミダーゼ又はスフィンゴシンキナーゼ活性に関係する疾病又は疾患を治療又は予防するための医薬組成物。
- 酸性セラミダーゼを含むサンプルを、有効量の酸性セラミダーゼ阻害剤のエステルプロドラッグと、該プロドラッグが加水分解してこの阻害剤になる条件下で、接触させる段階から成る、インビトロ又は人体を除くインビボで、酸性セラミダーゼを阻害する方法であって、該プロドラッグが、請求項1〜4のいずれか一項に記載の化合物である方法。
- 下記化学式(Ia)
nは0〜13の整数であり;
R1は、NH2、NHR6、NR6R7及びN-複素環から成る群から選択され;
R2は、水素原子及びアルキル基から成る群から選択され;
R3は、水素原子、OH、NO2、NH2及びNHR9から成る群から選択され;
R4は、水素原子、CH3、CH2OH及びCH2O-C(=O)-CH(R8)NR6R7から成る群から選択され;
R5は、水素原子、OH、=O及びOC(=O)CH(R8)NR6R7から成る群から選択され、各R6、R7及びR8は、独立して水素原子、アルキル基、アラルキル基及びアリール基から成る群から選択され;
R9は、C(=O)-(CH2)mR10であり、ここでmは5〜10の整数であり;
R10は、水素原子、アルキル基、シクロアルキル基又は複素環であり;
Xは、酸素原子、NH及び硫黄原子から成る群から選択され;及び
Yは、CH2又はNHである)
の構造を持つ化合物、又はこの化合物の医薬的に許容された塩である、酸性セラミダーゼを阻害するための化合物。 - R1がNR6R7であり、R6及びR7がそれぞれアルキル基である請求項7に記載の化合物。
- 前記化合物が、(1R, 2R)-2-[N-(12'-{1"-イミダゾール}-ドデカノイル)-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール (LCL433); (1R, 2R)-2-[N-(12'-{1"-モルホリン}-ドデカノイル)-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール (LCL449); (1R, 2R)-2-[N-(12'-アミノ-ドデカノイル)-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール (LCL463); (1R, 2R)-2-[N-(12'-N,N-ジメチルアミノ-ドデカノイル)-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール (LCL464); (1R, 2R)-2-[N-(6'-{N-オクチルアミノ}-ヘキサノイル)-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール(LCL488);及び(1R, 2R)-2-[N-{12'-N-メチル-アミノ}-ドデカノイル]-アミノ]-1-(4"-ニトロフェニル)-1,3-プロパンジオール (LCL506)から成る群から選択される請求項7に記載の化合物。
- (a)請求項7〜9のいずれか一項に記載の化合物、及び(b)医薬的に許容された担体から成る、患者における好ましくないセラミダーゼ又はスフィンゴシンキナーゼ活性に関係する疾病又は疾患を治療又は予防するための医薬組成物。
- 酸性セラミダーゼを含むサンプルを、有効量の請求項7〜9のいずれか一項に記載の化合物に接触させる段階から成る、インビトロ又は人体を除くインビボで、酸性セラミダーゼを阻害する方法であって、この阻害が、恒久的なリソソーム不安定化及び/又は酸性セラミダーゼのタンパク質分解なしに行われる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11185208P | 2008-11-06 | 2008-11-06 | |
US61/111,852 | 2008-11-06 | ||
PCT/US2009/063586 WO2010054223A1 (en) | 2008-11-06 | 2009-11-06 | Lysosomotropic inhibitors of acid ceramidase |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012508249A JP2012508249A (ja) | 2012-04-05 |
JP2012508249A5 true JP2012508249A5 (ja) | 2012-12-20 |
JP5721631B2 JP5721631B2 (ja) | 2015-05-20 |
Family
ID=42153265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011535698A Active JP5721631B2 (ja) | 2008-11-06 | 2009-11-06 | 酸性セラミダーゼのリソソーム親和性阻害剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8697379B2 (ja) |
EP (1) | EP2348839B1 (ja) |
JP (1) | JP5721631B2 (ja) |
CN (1) | CN102368905B (ja) |
AU (1) | AU2009313400A1 (ja) |
BR (1) | BRPI0921278A2 (ja) |
CA (1) | CA2742866C (ja) |
HK (1) | HK1167999A1 (ja) |
RU (1) | RU2011117722A (ja) |
WO (1) | WO2010054223A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1814854B1 (en) | 2004-10-29 | 2015-02-25 | MUSC Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
US8592419B2 (en) | 2004-10-29 | 2013-11-26 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
EP2348839B1 (en) | 2008-11-06 | 2017-04-05 | MUSC Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
EP2384118A4 (en) * | 2008-12-30 | 2012-01-11 | Musc Found For Res Dev | SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE |
WO2013036875A1 (en) | 2011-09-07 | 2013-03-14 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
ITMI20120923A1 (it) | 2012-05-28 | 2013-11-29 | Fond Istituto Italiano Di Tec Nologia 45 | Inibitori della ceramidasi acida e loro usi come medicamenti |
ITMI20120921A1 (it) * | 2012-05-28 | 2013-11-29 | Fond Istituto Italiano Di Tec Nologia 45 | Inibitori della ceramidasi acida e loro usi come medicamenti |
US9492514B2 (en) * | 2012-06-01 | 2016-11-15 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
DK2968479T3 (da) | 2013-03-14 | 2019-08-12 | Icahn School Med Mount Sinai | Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
WO2015119393A1 (ko) * | 2014-02-04 | 2015-08-13 | (주)네오팜 | 발모촉진용 또는 탈모방지용 조성물 |
KR20150091983A (ko) * | 2014-02-04 | 2015-08-12 | (주)네오팜 | 발모촉진용 또는 탈모방지용 조성물 |
WO2015173168A1 (en) | 2014-05-12 | 2015-11-19 | Fondazione Istituto Italiano Di Tecnologia | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
WO2015173169A1 (en) | 2014-05-12 | 2015-11-19 | Fondazione Istituto Italiano Di Tecnologia | Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
US11426371B2 (en) | 2017-04-28 | 2022-08-30 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
CN110598636B (zh) * | 2019-09-09 | 2023-01-17 | 哈尔滨工业大学 | 一种基于特征迁移的舰船目标识别方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2515465A (en) | 1946-03-22 | 1950-07-18 | Merck & Co Inc | Preparation of 2-alkyl-4-isopropylidene-5(4)-oxazolones |
GB630712A (en) | 1946-03-22 | 1949-10-19 | Merck & Co Inc | Process of preparing intermediates useful in the preparation of penicill amine |
GB844431A (en) * | 1957-12-07 | 1960-08-10 | Boehringer & Soehne Gmbh | Injectable aqueous solutions of chloramphenicol |
US3466292A (en) | 1966-05-13 | 1969-09-09 | Upjohn Co | Diazatricyclododecanediones and diazatricyclododecadiendiones |
GB1307539A (en) * | 1970-06-25 | 1973-02-21 | Smith Kline French Lab | Thiourea derivatives |
US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
DE2408813A1 (de) | 1974-02-23 | 1975-09-04 | Agfa Gevaert Ag | N-carbamoyloxypyridiniumsalze und verfahren zur herstellung derselben |
US4481203A (en) | 1977-04-05 | 1984-11-06 | Taiho Pharmaceutical Company, Limited | Composition containing 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil |
DE2817494A1 (de) | 1977-05-03 | 1978-11-09 | Continental Pharma | Aminoalkohol-derivat |
US4151198A (en) | 1978-06-02 | 1979-04-24 | American Cyanamid Company | Resolution of N-acyl-DL (+)-phenylalanines |
US4283541A (en) | 1980-05-27 | 1981-08-11 | Usv Pharmaceutical Corporation | Pyridylacyl-hydroxamates |
US4544670A (en) | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
EP0310545A3 (de) | 1987-09-02 | 1989-07-26 | Ciba-Geigy Ag | Cyanoguanidine als Härter für Epoxidharze |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5679350A (en) | 1992-05-28 | 1997-10-21 | The University Of Toledo | Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material |
US5369030A (en) | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
AU7823894A (en) * | 1993-08-27 | 1995-03-21 | Vrije Universiteit | New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor |
WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US5830916A (en) | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
DE19621038A1 (de) | 1996-05-24 | 1997-11-27 | Boehringer Ingelheim Kg | Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten |
US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
US6610835B1 (en) | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
WO2000027883A2 (en) | 1998-11-06 | 2000-05-18 | Musc Foundation For Research Development | A method of treating tumors using fas-induced apoptosis |
AU2001252506A1 (en) | 2000-04-19 | 2001-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US6756504B2 (en) | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US6696081B2 (en) | 2000-06-09 | 2004-02-24 | Duke University | Carbohydrate based lipid compositions and supramolecular structures comprising same |
WO2002022175A2 (en) | 2000-09-11 | 2002-03-21 | Musc Foundation For Research Development | Method and composition for treating tumors by selective induction of apoptosis |
AU2002320470A1 (en) | 2001-07-11 | 2003-01-29 | Musc Foundation For Research Development | Modulators of ceramidase and methods of use based thereon |
JP2004210733A (ja) * | 2003-01-07 | 2004-07-29 | Kyowa Hakko Kogyo Co Ltd | アリールスルファマート誘導体 |
BRPI0407055A (pt) * | 2003-01-27 | 2006-01-17 | Pfizer Prod Inc | Derivados de isotiazol |
JP2006518390A (ja) | 2003-02-19 | 2006-08-10 | エンダシア,インコーポレイテッド | A1アデノシンレセプターアンタゴニスト |
EP1707211A4 (en) * | 2003-11-28 | 2009-08-05 | Takara Bio Inc | Ceramidase INHIBITORS |
BRPI0508461B8 (pt) | 2004-03-05 | 2021-05-25 | Hoffmann La Roche | diaminopirimidinas, seus usos, e composição farmacêutica |
JP2005336174A (ja) * | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 変形性関節症治療剤 |
US8592419B2 (en) | 2004-10-29 | 2013-11-26 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
EP1814854B1 (en) | 2004-10-29 | 2015-02-25 | MUSC Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
JP2006298807A (ja) * | 2005-04-19 | 2006-11-02 | Lead Chemical Co Ltd | 新規化合物及びその用途 |
EP2314574A1 (en) | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors |
CN101460168B (zh) * | 2006-03-31 | 2013-07-17 | 詹森药业有限公司 | 作为组胺h4受体调节剂的苯并咪唑-2-基吡啶 |
CA2672795A1 (en) * | 2006-12-13 | 2008-06-26 | Schering-Plough Ltd. | Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof |
EP2348839B1 (en) | 2008-11-06 | 2017-04-05 | MUSC Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
EP2384118A4 (en) | 2008-12-30 | 2012-01-11 | Musc Found For Res Dev | SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE |
-
2009
- 2009-11-06 EP EP09825496.4A patent/EP2348839B1/en active Active
- 2009-11-06 US US13/127,888 patent/US8697379B2/en not_active Expired - Fee Related
- 2009-11-06 WO PCT/US2009/063586 patent/WO2010054223A1/en active Application Filing
- 2009-11-06 CN CN200980154007.6A patent/CN102368905B/zh not_active Expired - Fee Related
- 2009-11-06 BR BRPI0921278-7A patent/BRPI0921278A2/pt not_active Application Discontinuation
- 2009-11-06 RU RU2011117722/13A patent/RU2011117722A/ru not_active Application Discontinuation
- 2009-11-06 JP JP2011535698A patent/JP5721631B2/ja active Active
- 2009-11-06 CA CA2742866A patent/CA2742866C/en not_active Expired - Fee Related
- 2009-11-06 AU AU2009313400A patent/AU2009313400A1/en not_active Abandoned
-
2012
- 2012-09-07 HK HK12108760.7A patent/HK1167999A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012508249A5 (ja) | ||
JP2008512490A5 (ja) | ||
JP2007505877A5 (ja) | ||
JP2008535902A5 (ja) | ||
JP2009504763A5 (ja) | ||
RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
JP2010509356A5 (ja) | ||
JP2013525318A5 (ja) | ||
JP2011529918A5 (ja) | ||
JP2006505543A5 (ja) | ||
JP2010530881A5 (ja) | ||
JP2009515887A5 (ja) | ||
JP2009504764A5 (ja) | ||
JP2008535903A5 (ja) | ||
JP2013518050A5 (ja) | ||
JP2006306885A5 (ja) | ||
RU2011117722A (ru) | Лизосомотропные ингибиторы кислой церамидазы | |
EP4188373A1 (en) | Low molecular weight protein degraders and their applications | |
JP2008509166A5 (ja) | ||
PT2459553E (pt) | Furazanobenzimidazoles como precursores de fármacos para tratar doenças neoplásicas ou autoimunes | |
JP2010501479A5 (ja) | ||
JP2010527985A5 (ja) | ||
JP2014510149A5 (ja) | ||
JP2013514980A5 (ja) | ||
JP2010527984A5 (ja) |